Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Puretech Health Plc ADR (PRTC)

Puretech Health Plc ADR (PRTC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 476,924
  • Shares Outstanding, K 23,942
  • Annual Sales, $ 3,330 K
  • Annual Income, $ -65,700 K
  • EBIT $ 0 M
  • EBITDA $ -141 M
  • 60-Month Beta 1.20
  • Price/Sales 145.84
  • Price/Cash Flow N/A
  • Price/Book 1.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.30 unch
on 12/26/24
24.99 -22.77%
on 11/27/24
-1.94 (-9.13%)
since 11/26/24
3-Month
19.02 +1.47%
on 10/02/24
24.99 -22.77%
on 11/27/24
-1.39 (-6.72%)
since 09/26/24
52-Week
19.02 +1.47%
on 10/02/24
34.00 -43.24%
on 04/04/24
-5.81 (-23.14%)
since 12/26/23

Most Recent Stories

More News
This Emerging Market Could Be the Next Big Thing in Biotech

Medicines to treat the many symptoms of long COVID are in high demand already.

PRTC : 19.30 (-3.11%)
PFE : 26.63 (-0.41%)
ARGX : 626.02 (-0.63%)
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted today that its Founded Entity, Akili, Inc. (Nasdaq: AKLI) (“Akili”),...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
AKLI : 0.4320 (-0.62%)
PureTech Announces Annual Results for Year Ended December 31, 2022

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”) today announces its results for the year ended December 31, 2022, as well as its cash balance as of the first quarter...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
BIIB : 148.75 (-0.18%)
KRTX : 329.83 (+0.03%)
VOR : 0.8500 (-2.80%)
AKLI : 0.4320 (-0.62%)
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences , a clinical-stage...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
PureTech Health: Notice of Results

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Friday, April 28, 2023, at 2:00 AM EDT/ 7:00 AM BST. The report...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
RPRX : 25.30 (+0.28%)
PureTech to Present at the Barclays Global Healthcare Conference

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Sonde Health , a health technology...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, today announced...

PRTC : 19.30 (-3.11%)
PRTC.LN : 154.800 (-1.02%)

Business Summary

PureTech Health plc is a clinical-stage biotherapeutics company. It engages in discovering, developing and commercializing medicines for devastating diseases, including inflammatory and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological...

See More

Key Turning Points

3rd Resistance Point 20.07
2nd Resistance Point 20.04
1st Resistance Point 19.98
Last Price 19.30
1st Support Level 19.89
2nd Support Level 19.86
3rd Support Level 19.80

See More

52-Week High 34.00
Fibonacci 61.8% 28.28
Fibonacci 50% 26.51
Fibonacci 38.2% 24.74
Last Price 19.30
52-Week Low 19.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar